Investigating the analgesic effects of rovacaine compounds in ACL surgery

Comparison of the analgesic effects of intra-articular injection of Ropivacaine7.5% with dexmedetomidine and Ropivacaine7.5% with magnesium and Ropivacaine7.5% with ketamine after ACL surgery

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230626058586N2

Enrollment

Registered

2024-01-03

Start date

2024-01-21

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after ACL surgery.

Interventions

Intervention 1: Intervention group: Intervention group: intra-articular injection of ropivacaine 7.5% with dexmedetomidine (100 micrograms in 10 ml of normal saline). Manufacturer of Rupivacaine: Sina

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: age between 18-60 A candidate for elective ACL surgery Physical status ASA I and II

Exclusion criteria

Exclusion criteria: Allergy to the drugs used in the study Pregnancy and breastfeeding Having diabetes alcohol consumption Severe liver and kidney failure

Design outcomes

Primary

Measure	Time frame
Pain level of patients after ACL surgery. Timepoint: 1, 2, 6, 12 and 24 hours after the operation. Method of measurement: Using the Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad reza Moshari

Shahid Beheshti University of Medical Sciences

rmoshari@yahoo.com0098 21 230311

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026